Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 65
Filtrar
1.
Rev. esp. anestesiol. reanim ; 58(9): 585-587, nov. 2011.
Artigo em Espanhol | IBECS | ID: ibc-93713

RESUMO

El síndrome de MNGIE (encefalopatía mitocondrial neuro-gastrointestinal) es una miopatía mitocondrial caracterizada clínicamente por leucoencefalopatía, neuropatía periférica, ptosis, oftalmoparesia y alteraciones en la motilidad gastrointestinal. Las miopatías mitocondriales son enfermedades infrecuentes con poca experiencia en su manejo anestésico. Describimos el procedimiento anestésico ante una intervención de urgencia por megacolon en una mujer de 26 años que presentaba síndrome de MNGIE. Se monitorizó con ECG, presión arterial invasiva, SpO2, EtCO2, espirometría, bloqueo neuromuscular y profundidad anestésica (entropía). Se realizó inducción de secuencia rápida con midazolam, fentanilo y propofol utilizando rocuronio como alternativa a succinilcolina y el mantenimiento con anestesia intravenosa con propofol, sin precisar repetir la dosis de bloqueante neuromuscular. No se apreciaron problemas intraoperatorios, procediendo a la extubación a las 2 horas de la llegada a la unidad de reanimación, tras comprobar el grado de bloqueo y sin necesidad de revertir el mismo(AU)


Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is characterized by leukoencephalopathy, peripheral neuropathy, ptosis, ophthalmoplegia, and gastrointestinal dysmotility. Mitochondrial myopathies are rare diseases and little is known of how to manage them when the patient requires anesthesia. We describe the anesthetic procedure used during emergency surgery for megacolon in a 26-year-old woman with MNGIE. Variables monitored were electrocardiogram, invasive arterial pressure, oxygen saturation by pulse oximetry, end-tidal carbon dioxide pressure, neuromuscular block, and depth of anesthesia (entropy). Rapid sequence induction was accomplished with midazolam, fentanyl, propofol, and rocuronium as an alternative to succinylcholine. Anesthesia was maintained with intravenous propofol; a second dose of the neuromuscular blocker was not required. No intraoperative problems developed and extubation was possible 2 hours after arrival in the postoperative critical care unit, once we had checked the level of block to confirm that reversion was not required(AU)


Assuntos
Humanos , Feminino , Adulto , Encefalomiopatias Mitocondriais/tratamento farmacológico , Encefalomiopatias Mitocondriais/reabilitação , Leucoencefalopatias/complicações , Leucoencefalopatias/diagnóstico , Megacolo/complicações , Bloqueadores Neuromusculares/administração & dosagem , Bloqueadores Neuromusculares/uso terapêutico , Anestesia Intravenosa/métodos , Anestesia Intravenosa , Pressão Arterial , Pressão Arterial/fisiologia , Espirometria/métodos , Espirometria , Midazolam/uso terapêutico , Fentanila/uso terapêutico , Propofol/uso terapêutico , Succinilcolina/uso terapêutico
2.
Magn Reson Med ; 65(2): 329-39, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20939087

RESUMO

Proton magnetic resonance spectroscopic imaging ((1) H-MRSI) has been advocated as a valuable tool for prostate cancer diagnosis. However, a barrier to widespread clinical use of this technique is the lack of robust quantification methods that yield reproducible results in an institution-independent manner. The main goal of this study was to develop a standardized and fully automated approach (LCModel-based) for quantitative prostate (1) H-MRSI. To this end, a dedicated basis set was constructed by the combination of simulated (citrate, Cit; choline, Cho, and creatine, CR) and experimentally acquired (spermine, Spm) spectra. The overlapping Spm, Cho, and Cr could be resolved and quantified individually, thus allowing for the independent assessment of glandular (Cit and Spm) and proliferative (Cho) components. Several metabolite ratios were calculated and compared to the histologic findings of prostatectomy specimens from 10 prostate cancer patients with Gleason scores (3 + 3) and (3 + 4). The Cho mole fraction and the Cho/(Cit + Spm) ratio were found to best discriminate between prostate cancer and healthy tissue. The comparison between the quantitative MRSI results and the histologic findings suggests that no correlation exists between the detected metabolic alterations and the Gleason score of low-grade tumors.


Assuntos
Adenocarcinoma/metabolismo , Espectroscopia de Ressonância Magnética , Próstata/metabolismo , Próstata/patologia , Neoplasias da Próstata/metabolismo , Neoplasias da Próstata/patologia , Adenocarcinoma/patologia , Colina/análise , Ácido Cítrico/análise , Creatina/análise , Humanos , Técnicas In Vitro , Masculino , Imagens de Fantasmas , Espermina/análise
3.
Rev Esp Anestesiol Reanim ; 58(9): 585-7, 2011 Nov.
Artigo em Espanhol | MEDLINE | ID: mdl-22279879

RESUMO

Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is characterized by leukoencephalopathy, peripheral neuropathy, ptosis, ophthalmoplegia, and gastrointestinal dysmotility. Mitochondrial myopathies are rare diseases and little is known of how to manage them when the patient requires anesthesia. We describe the anesthetic procedure used during emergency surgery for megacolon in a 26-year-old woman with MNGIE. Variables monitored were electrocardiogram, invasive arterial pressure, oxygen saturation by pulse oximetry, end-tidal carbon dioxide pressure, neuromuscular block, and depth of anesthesia (entropy). Rapid sequence induction was accomplished with midazolam, fentanyl, propofol, and rocuronium as an alternative to succinylcholine. Anesthesia was maintained with intravenous propofol; a second dose of the neuromuscular blocker was not required. No intraoperative problems developed and extubation was possible 2 hours after arrival in the postoperative critical care unit, once we had checked the level of block to confirm that reversion was not required.


Assuntos
Anestesia/métodos , Pseudo-Obstrução Intestinal , Encefalomiopatias Mitocondriais , Adulto , Tratamento de Emergência , Feminino , Humanos , Pseudo-Obstrução Intestinal/complicações , Megacolo/complicações , Megacolo/cirurgia , Encefalomiopatias Mitocondriais/complicações , Distrofia Muscular Oculofaríngea , Oftalmoplegia/congênito
5.
Arch. esp. urol. (Ed. impr.) ; 61(3): 428-431, abr. 2008. ilus
Artigo em Es | IBECS | ID: ibc-64189

RESUMO

Objetivo: Presentación de un caso clínico de migración proximal de catéter doble J. Revisión de la literatura que lo provocan y las maniobras para evitar dicha complicación. Método/Resultados: Mujer de 48 años sometida a cirugía ginecológica que presenta uropatía obstructiva derecha durante el postoperatorio. Después de colocación de catéter doble J se objetiva una migración proximal del mismo que se resuelve mediante nefrostomía percutánea y colocación anterógrada de catéter ureteral. Conclusiones: La elección adecuada de la longitud del catéter y la colocación distal del mismo son elementos claves para evitar esta complicación (AU)


Objective: To report one case of proximal migration of ureteral stent. To perform a bibliographic review about other cases and management to avoid this complication. Methods/Results: 48-year-old woman who presents right obstructive uropathy after gynecologic surgery. After the introduction of the right ureteral stent we observed a proximal stent migration. We put on a right nephrostomy tube and antergrade ureteral stent. Conclusions: The right stent length and proper location of the distal tip are important factors to avoid this complication (AU)


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Ablação por Cateter/métodos , Nefrostomia Percutânea/métodos , Obstrução Ureteral/cirurgia , Cateterismo Urinário/instrumentação , Cateterismo Urinário/métodos , Urografia/métodos , Ureteroscopia/organização & administração , Histerectomia/efeitos adversos , Histerectomia/métodos , Radiografia Abdominal/métodos , Hematúria/complicações , Pelve Renal/cirurgia , Pelve Renal , Doença Iatrogênica/epidemiologia
6.
Actas Urol Esp ; 30(9): 879-95, 2006 Oct.
Artigo em Espanhol | MEDLINE | ID: mdl-17175928

RESUMO

UNLABELLED: The objective of this article is to quote under the form of a document the opinions expressed by the participants of the round table "Lasers in Urology Today" (january 2006). The material and method used is the compilation of critical and updated notions on the usefulness of lasers in urology, supplemented by bibliographic references, a limited iconography. The results achieved by lasers today enable us to state that: Holmium laser is the choice treatment for in situ lithotripsy; however, it has not significantly improved previous results when treating urologic tumours and stenoses. Nowadays we have two types of lasers: KTP and HoL, which obtain results similar to surgery regarding BPH, but with reduced morbidity. The usefulness of laser in laparoscopic surgery is still under development. CONCLUSION: Lasers in Urology Today play an active role in in situ lithotripsy (HoL), and a competitive one in BPH surgery (KTP and HoL). Regarding the rest of indications, i.e. tumours, stenoses, laparoscopic surgery, etc., further studies and enough follow-up times are still needed.


Assuntos
Fotocoagulação a Laser , Terapia a Laser , Doenças Urológicas/cirurgia , Desenho de Equipamento , Humanos , Terapia a Laser/instrumentação , Litotripsia a Laser , Cálculos Urinários/terapia
7.
Actas urol. esp ; 30(9): 879-895, oct. 2006. ilus, tab
Artigo em Es | IBECS | ID: ibc-049448

RESUMO

El objetivo de este artículo, es reproducir en forma de texto las opiniones vertidas por los componentes de laMesa Redonda "Lásers en Urología Hoy", durante su celebración (enero 2006). El material y método empleados ha sido la recopilación de los conceptos críticos y actuales sobre la utilidad de los lásers en urología, acompañados de bibliografía/iconografía limitada y seleccionada. Los resultados conseguidos por los lásers en la actualidad permiten establecer que: EL láser Holmium es el tratamiento de elección como litotricia in situ pero que no ha mejorado significativamente los resultados precedentes, en el tratamiento de los tumores y estenosis urológicos. Disponemos hoy de dos tipos de lásers: KTP y HoL que consiguen resultados similares a los de la cirugía en la HBP, pero con menor morbilidad. La utilidad del láser en cirugía laparoscópica está todavía en desarrollo. En conclusión: los Lásers en Urología Hoy desempeñan un papel electivo en litotricia in situ (HoL) y competitivo en cirugía de la HBP (KTP y HoL). En el resto de sus indicaciones: tumores, estenosis, cirugía laparoscópica etc., se precisan estudios y tiempo de seguimiento suficientes para establecer conclusiones fiables


The objective of this article is to quote under the form of a document the opinions expressed by the participants of the round table "Lasers in Urology Today" (january 2006). The material and method used is the compilation of critical and updated notions on the usefulness of lasers in urology, supplemented by bibliographic references, a limited iconography. The results achieved by lasers today enable us to state: Holmium laser is the choice treatment for in situ lithotripsy; however, it has not significantly improved previous results when treating urologic tumours and stenoses. Nowadays we have two types of lasers: KTP and HoL, which obtain results similar to surgery regarding BHP, but with reduced morbidity. The usefulness of laser in laparoscopic surgery is still under development. Conclusion: Lasers in Urology Today play an active role in in situ lithotripsy (HoL), and competitive one in BPH surgery (KTP and HoL). Regarding the rest of indications, i. e. tumours, stenoses, laparoscopic surgery, etc., further studies and enough follow-up times are still needed


Assuntos
Humanos , Lasers/uso terapêutico , Doenças Urológicas/cirurgia , Terapia a Laser , Litotripsia a Laser , Hiperplasia Prostática/cirurgia , Estreitamento Uretral/cirurgia , Laparoscopia , Neoplasias Urológicas/cirurgia
8.
Rev Clin Esp ; 204(8): 398-404, 2004 Aug.
Artigo em Espanhol | MEDLINE | ID: mdl-15274762

RESUMO

OBJECTIVE: Evaluation of the effect of amlodipine on the hospitalizations for cardiovascular events (CVE) and their associated costs in patients with ischemic cardiopathy. METHODS: Data from the multicenter, randomized, double-blind, placebo-controlled PREVENT (Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial) clinical trial were utilized. A tree-type model of decision was used in order to analyze the incremental costs expected from the treatment with amlodipine with regard to placebo. Hospitalization costs were estimated with regard to the DRG weights of the American Medicare adapted for the costs of average stay available in our environment. RESULTS: Amlodipine reduced significantly the incidence of CVE that required hospitalization in contrast to placebo; 0.60 +/- 1.16 versus 0.77 +/- 1.31 (average +/- SD), p < 0.05. The expected direct expenses due to hospitalizations were higher in the placebo group than in the amlodipine group (saving of 205.76 Euro/patient). Total cost for patient in the amlodipine group was 1,723.52 Euro while in the placebo group was 1,929.28 Euro. When the relation cost/price shifted in the sensitivity analysis from 1.20 to 0.66 (cost of every hospitalization ranged between + 20% and -34%), the saving fluctuated from 330.56 Euro to 0. Accordingly, the breakeven point of the cost/price relation it is 0.66, and above this the treatment with amlodipine still generates savings in regard to its cost. CONCLUSIONS: Amlodipine is cost-effective in the treatment of the patients with ischemic cardiopathy, being able to reduce the hospital costs related to ischemic episodes in this type of patients.


Assuntos
Anlodipino/economia , Anti-Hipertensivos/economia , Doenças Cardiovasculares/economia , Hospitalização/estatística & dados numéricos , Anlodipino/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Doenças Cardiovasculares/tratamento farmacológico , Custos e Análise de Custo , Método Duplo-Cego , Feminino , Hospitalização/economia , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
9.
Actas Urol Esp ; 27(9): 726-31, 2003 Oct.
Artigo em Espanhol | MEDLINE | ID: mdl-14626684

RESUMO

Nutcracker syndrome is caused by compression of left renal vein between the aorta and the superior mesenteric artery. This phenomenon results in left renal venous hypertension, left gonadal vein varices and unilateral hematuria. We report a typical case of nutcracker syndrome and we review the literature in an effort to explain this pathology.


Assuntos
Hematúria/etiologia , Túbulos Renais Coletores , Artéria Renal , Adolescente , Humanos , Nefropatias/diagnóstico por imagem , Nefropatias/etiologia , Túbulos Renais Coletores/diagnóstico por imagem , Masculino , Radiografia , Artéria Renal/diagnóstico por imagem , Síndrome , Doenças Vasculares/complicações , Doenças Vasculares/diagnóstico por imagem
10.
Actas urol. esp ; 27(9): 726-731, oct. 2003.
Artigo em Es | IBECS | ID: ibc-25217

RESUMO

El síndrome del cascanueces está causado por una compresión de la vena renal entre la aorta y la arteria mesentérica superior. Este fenómeno resulta en una hipertensión de la vena renal izquierda, varices en la vena gonadal izquierda y hematuria unilateral. Comunicamos un caso típico de síndrome de cascanueces y se lleva a cabo una revisión de la literatura reciente para tratar de explicar esta patología (AU)


Nutcracker syndrome is caused by compression of left renal vein between the aorta and the superior mesenteric artery. This phenomenon results in left renal venous hypertension, left gonadal vein varices and unilateral hematuria. We report a typical case of nutcracker syndrome and we review the literature in an effort to explain this pathology (AU)


Assuntos
Adolescente , Masculino , Humanos , Artéria Renal , Túbulos Renais Coletores , Síndrome , Doenças Vasculares , Nefropatias , Hematúria
11.
Hipertensión (Madr., Ed. impr.) ; 20(5): 195-199, jun. 2003. tab, graf
Artigo em Es | IBECS | ID: ibc-22540

RESUMO

Objetivo. Conocer el grado de control de la presión arterial (PA) (óptimo<=140/90 mmHg; subóptimo 140/90 mmHg) en hipertensos que acuden a los centros de Atención Primaria en Granada durante el día 24 de noviembre de 1999.Diseño. Estudio observacional, descriptivo y transversal. Ámbito del estudio. Centros de Atención Primaria del área de Granada. Sujetos. Pacientes ambulatorios de ambos sexos, diagnosticados de hipertensión arterial, que acuden a la consulta de Atención Primaria el día 24 de noviembre de 1999.Mediciones. Análisis descriptivo de las diferentes variables del estudio: datos demográficos, motivo de la consulta, anamnesis, exploración física, analítica, tratamientos concomitantes, intervención propuesta tras la visita. Resultados. Se consiguió una muestra de 627 pacientes hipertensos. La edad media fue de 63,8 años (DE ñ 10,6), siendo el rango de edades entre 27 y 90 años. El 37,3 por ciento eran hombres y el 62,7 por ciento mujeres. En la primera medición se obtienen valores medios de PA sistólica (PAS) de 149 mmHg y PA diastólica (PAD) de 85,7 mmHg. En la segunda medición (tras 5 minutos de reposo) la PAS fue de 147 mmHg y la PAD de 84 mmHg, siendo estas diferencias estadísticamente significativas (p<0,001). Distribución del tratamiento antihipertensivo: inhibidores de la enzima de conversión de la angiotensina (IECA), 40,1 por ciento; diuréticos, 6,9 por ciento; calcioantagonistas, 16,5 por ciento; betabloqueantes, 3,4 por ciento; alfabloqueantes, 2,1 por ciento y terapia combinada, 31,1 por ciento. Cumplimiento: el 59,2 por ciento afirmaba seguir correctamente el tratamiento antihipertensivo. Según los valores finales de PA, encontramos un 17,9 por ciento de control óptimo y un 30,3 por ciento de control subóptimo. Conclusiones. Los niveles de control de la PA alcanzado en nuestro estudio concuerdan con los obtenidos en otros estudios, nacionales y no nacionales de características similares (AU)


Assuntos
Adulto , Idoso , Feminino , Masculino , Pessoa de Meia-Idade , Idoso de 80 Anos ou mais , Humanos , Atenção Primária à Saúde , Hipertensão/tratamento farmacológico , Anti-Hipertensivos/administração & dosagem , Estudos Transversais , Espanha , Fatores de Risco
12.
Farm Hosp ; 27(2): 93-100, 2003.
Artigo em Espanhol | MEDLINE | ID: mdl-12717564

RESUMO

Arsenic trioxide has drawn renewed interest in onco-haematological therapy. Based on a number of studies quoted in this paper, it has been approved by FDA and EMEA for remission induction and consolidation therapy of acute promyelocytic leukaemia in patients refractory to treatment using trans-retinoic acid and anthracyclines. In addition to briefly discuss available therapeutic resources against this disease, this review attempts to provide an in-depth view of this drugâs characteristics and efficacy, as shown in several studies.


Assuntos
Antineoplásicos/uso terapêutico , Arsenicais/uso terapêutico , Leucemia Promielocítica Aguda/tratamento farmacológico , Óxidos/uso terapêutico , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Antineoplásicos/farmacologia , Trióxido de Arsênio , Arsenicais/administração & dosagem , Arsenicais/efeitos adversos , Arsenicais/farmacologia , Ensaios Clínicos como Assunto , Humanos , Óxidos/administração & dosagem , Óxidos/efeitos adversos , Óxidos/farmacologia
13.
Arch Esp Urol ; 54(4): 297-310, 2001 May.
Artigo em Espanhol | MEDLINE | ID: mdl-11455763

RESUMO

OBJECTIVE: To briefly describe the life and works of D.F.J.B. Trehet, a physician of the city of Rouen (France), who was the first to describe the "osseous points" in a renal calculus. Trèhet has not been recognized or referenced for this original observation in the urological publications. METHODS: Trehet lived in the period of the Enlightenment and endured the upheavals of the French Revolution. Data gleaned from several sources have permitted and elaborate description of this French physician from both the social and professional perspectives. RESULTS: After completing his studies at the Hôtel Dieu in Rouen, D.F.J.B. Trehet pursued his education at the School of Health in Paris. He read his doctorate's thesis at the Paris School of Medicine in 1803 and published his observation of a renal calculus "with osseous points" in 1812. Other studies by D.F.J.B. Trehet were also published in Le Journal de Médecine, Chirurgie et Pharmacie. CONCLUSIONS: D.F.J.B. Trehet should be recognized as the first to describe an osseous renal calculus.


Assuntos
Ossificação Heterotópica/história , Cálculos Urinários/história , França , História do Século XVIII , História do Século XIX , Humanos
14.
Hipertensión (Madr., Ed. impr.) ; 18(4): 157-164, mayo 2001. ilus, tab, graf
Artigo em Es | IBECS | ID: ibc-1007

RESUMO

Tras un período de lavado de 2 semanas libre de fármacos y otras 2 semanas de administración de un placebo se han incluido un total de 114 pacientes, mayores de 18 años, diagnosticados de hipertensión arterial (HTA) leve a moderada (presión arterial diastólica [PAD]: 90-119 mmHg). El diseño del estudio fue simple ciego y se comparó la eficacia y tolerancia de amlodipino (AML), con un rango de 5-10 mg en dosis única diaria, frente a nifedipino GITS (NGITS), con un rango de 30-60 mg también en dosis única diaria, durante 2 meses de tratamiento. Se realizaron 2 monitorizaciones de la presión arterial durante 24 horas (MAPA) a cada paciente, una basal, al finalizar la fase placebo, y otra final, transcurridos los 2 meses de tratamiento activo; asimismo para la MAPA final se consideraron 2 subgrupos de pacientes distribuidos aleatoriamente: un subgrupo control o de referencia (incluyendo finalmente 39 MAPA válidos) que tomaron la medicación el día en que se les colocaba la grabadora, y un segundo subgrupo que omitieron la dosis del fármaco correspondiente el día que les era colocado el dispositivo grabador de la MAPA (con 41 MAPA válidos analizados). A cada paciente se le efectuaron controles semanales de la presión arterial (PA), frecuencia cardíaca (FC) y acontecimientos adversos, así como electrocardiograma y analítica (bioquímica y hematimetría) al comienzo y a la finalización del estudio. Se consideró hipertenso, mediante el criterio de a MAPA, todo paciente con una PA media (PAM) en el registro de 24 horas igual o superior a 135 mmHg de PA sistólica (PAS) y 85 mmHg de PAD. El análisis estadístico de los datos se llevó a cabo mediante el protocolo por "intención de tratar" (ITT). Una vez obtenida la MAPA basal, 94 pacientes pasaron a la fase de tratamiento activo, siendo asignados aleatoriamente a alguno de los 2 grupos de tratamiento: 47 fueron incluidos en el grupo de pacientes tratados con AML y 47 fueron incluidos en el grupo tratado con NGITS.La PA, mediante la toma casual, se redujo de 163,3/100,3 a 138,7/87,4 mmHg en el grupo tratado con AML (p < 0,001) y de 163,2/99,7 a 139,9/86 mmHg en el tratado con NGITS (p < 0,001). La FC inicial y final con AML fue de 75,2 y 73,5 lpm, respectivamente (p = 0,128), mientras que con NGITS fue de 76,8 y de 77,2 lpm (p = 0,707), siendo estadísticamente significativas las diferencias entre las FC iniciales obtenidas para cada tratamiento (p = 0,017).No hubo diferencias significativas entre ambos tratamientos en las determinaciones analíticas. Comparando los resultados de la MAPA, para ambos tratamientos y para los subgrupos con y sin omisión de la última dosis se obtuvo que únicamente en el caso de un perfecto cumplimiento terapéutico ambos fármacos reducían de manera similar la PA de los pacientes en el estudio. Sin embargo, cuando se omitió una dosis, el descenso de PAS, PAD y PAM fue superior, en términos absolutos, en los pacientes tratados con AML, siendo, además, estadísticamente significativa la diferencia entre ambos tratamientos en el descenso conseguido de la PAS durante el período nocturno (p = 0,046) (AU)


Assuntos
Adulto , Feminino , Masculino , Humanos , Anlodipino/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Nifedipino/uso terapêutico , Vasodilatadores/uso terapêutico , Hipertensão/tratamento farmacológico , Resultado do Tratamento , Seguimentos , Monitorização Ambulatorial da Pressão Arterial , Pressão Sanguínea , Frequência Cardíaca , Método Simples-Cego
15.
Actas Urol Esp ; 25(1): 46-9, 2001 Jan.
Artigo em Espanhol | MEDLINE | ID: mdl-11284367

RESUMO

INTRODUCTION AND OBJECTIVE: Prostate biopsy is a basic step towards prostate cancer (Pca) diagnosis, but usually not free from complications. In this article we have reviewed the adverse effects of this procedure in our setting. MATERIAL AND METHODS: We studied in a prospective fashion the complications arising from transrectal prostate biopsy with the aid of a questionnaire fulfilled by 303 patients who underwent this procedure, within the context of a Pca screening program. All biopsies were transrectal ultrasound guided and randomly taken (sextant). A cleaning enema was applied the night before, and 100 mg of intramuscular tobramycin were administered prior of the procedure. RESULTS: Ninety patients (29.7%) had no adverse effects at all, and 136 (44.9%) reported at least one minor complication (hematuria, hemospermia, or autolimited dysuria). Lastly 77 (25.4%) presented with major complications--urinary retention, fever, need for medical assistance (primary or hospital care) or treatment. Thirty-five patients (11.5%) reported to present with fever after biopsy, 145 (47.8%) hematuria, 95 (31.3%) hemospermia, 77 (25.4%) rectal bleeding, 67 (22.1%) urinary difficulty, and 9 (2.9%) urinary retention. Up to 39 (12.8%) needed to visit their G.P., and 19 of them were referred to Hospital, where only 6 (1.9%) were admitted longer than 24 hours. No intensive care unit admittances or deaths were reported. CONCLUSIONS: The rate of post-transrectal biopsy adverse effects is high in our experience. This phenomenon could be explained, in part, due to data collecting by means of a self-administered questionnaire. Probably the high fever rate presented here could be diminished with other type of antibiotic prophylaxis.


Assuntos
Biópsia/efeitos adversos , Próstata/patologia , Biópsia/métodos , Humanos , Masculino , Estudos Prospectivos , Reto , Inquéritos e Questionários
16.
Actas urol. esp ; 25(1): 46-49, ene. 2001.
Artigo em Es | IBECS | ID: ibc-6041

RESUMO

OBJETIVO: Analizar los efectos adversos de la biopsia prostática transrectal en nuestro entorno. MATERIAL Y MÉTODOS: Los datos se recogieron mediante cuestionario cumplimentado por 303 pacientes que acudieron a la realización ambulatoria de la biopsia, en el contexto de un programa de detección precoz del CaP. Estas se llevaron a cabo de manera randomizada, sextante y ecodirigida. Los pacientes fueron preparados con un enema de limpieza la noche previa a la prueba, así como con 100 mg de tobramicina intramuscular inmediata-mente antes de la biopsia. RESULTADOS: Noventa pacientes (29,7 por ciento) no presentaron complicaciones, y 136 (44,9 por ciento) manifestaron algún efecto adverso leve (hematuria, hemospermia, o disuria autolimitados). Por último, 77 (25,4 por ciento) presentaron complicaciones no leves -retención urinaria, fiebre, necesidad de asistencia médica (primaria u hospitalaria) o de tratamiento-.Treinta y cinco pacientes (11,5 por ciento) manifestaron haber presentado fiebre tras la biopsia, 145 (47,8 por ciento) hematuria, 95 (31,3 por ciento) hemospermia, 77 (25,4 por ciento) sangrado rectal, 67 (22,1 por ciento) dificultad miccional, y 9 (2,9 por ciento) retención urinaria. Hasta 39 (12,8 por ciento) acudieron al médico de cabecera, y 19 de ellos fueron remitidos al Hospital, donde sólo 6 (1,9 por ciento) permanecieron ingresados más de 24 horas. No se registraron ingresos en UCI ni fallecimientos. CONCLUSIONES: El índice de efectos adversos de la biopsia transrectal es elevado en nuestra experiencia. Este fenómeno podría explicarse, en parte, por la recogida de datos mediante un cuestionario administrado al paciente. Probablemente pueda reducirse la tasa de fiebre post-biopsia mediante otro régimen de profilaxis antibiótica (AU)


Assuntos
Masculino , Humanos , Reto , Inquéritos e Questionários , Estudos Prospectivos , Próstata , Biópsia
17.
Arch Esp Urol ; 53(7): 581-95, 2000 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-11037651

RESUMO

OBJECTIVE: To review the embryological and clinical aspects of the different types of pyelocaliceal diverticula, with special reference to the differential diagnosis and treatment. METHODS: Images of type I and II pyelocaliceal diverticula are shown. The conditions that cause difficulty in making the differential diagnosis are discussed. RESULTS: Urography continues to be the diagnostic method preferred and is sometimes aided by retrograde ureteropyelography. CONCLUSIONS: Pyelocaliceal diverticula are cystic eventrations of the upper urinary tract lying within the renal parenchyma that communicate through a narrow channel into the main collecting system. They occur in 0.2 to 0.5% of the population and are congenital in origin. Calyceal diverticula are frequently found incidentally on routine excretory urograms, but patients may complain of flank pain, hematuria or recurrent urinary infections. In the past, treatment required open renal surgery. Endourologic procedures are widely utilized today.


Assuntos
Divertículo , Nefropatias , Diagnóstico Diferencial , Diagnóstico por Imagem , Divertículo/diagnóstico , Divertículo/embriologia , Divertículo/terapia , Humanos , Nefropatias/diagnóstico , Nefropatias/embriologia , Nefropatias/terapia , Imageamento por Ressonância Magnética , Tomografia Computadorizada por Raios X , Ultrassonografia , Urografia
18.
Hipertensión (Madr., Ed. impr.) ; 17(7): 296-301, oct. 2000. tab, graf
Artigo em Es | IBECS | ID: ibc-4018

RESUMO

Objetivo. Evaluar la seguridad de amlodipino en el tratamiento del paciente hipertenso no controlado con otros agentes hipotensores. Material y métodos. Estudio observacional, abierto, de cohortes, prospectivo, controlado, paralelo comparativo de farmacovigilancia. Se incluyeron 3.018 pacientes ambulatorios diagnosticados de hipertensión arterial grados I o II, según criterios del V Informe del JNC, y que no estaban controlados con su tratamiento farmacológico. El médico de Atención Primaria decidía en cada caso la asignación de un tratamiento de monoterapia con amlodipino o la administración del mismo en terapia combinada. Resultados. El 28,6 por ciento de los pacientes alcanzaron el objetivo terapéutico óptimo. Descendieron significativamente los niveles medios de presión arterial sistólica y diastólica desde el inicio al final del estudio (p < 0,05). Un 5,9 por ciento (157) de los pacientes presentaron acontecimientos adversos. No se mostraron diferencias estadísticamente significativas en cuanto a la frecuencia de acontecimientos adversos entre el grupo de monoterapia y el que recibió terapia combinada. La dosis de 5 mg consigue un control óptimo del 30 por ciento, control que puede incrementarse en un 23,2 por ciento adicional si se sube a 10 mg. Conclusiones. Amlodipino es un fármaco seguro y eficaz en el tratamiento de la hipertensión arterial en pacientes no controlados con otros fármacos hipotensores, tanto en monoterapia como en terapia combinada; el incremento de dosis no aumenta la frecuencia de acontecimientos adversos y amplía el porcentaje de pacientes controlados (AU)


Assuntos
Adolescente , Adulto , Idoso , Feminino , Masculino , Pessoa de Meia-Idade , Idoso de 80 Anos ou mais , Humanos , Anlodipino/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Hipertensão/tratamento farmacológico , Atenção Primária à Saúde , Resultado do Tratamento , Estudos de Coortes , Estudos Prospectivos , Quimioterapia Combinada
19.
Arch Esp Urol ; 53(10): 900-4, 2000 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-11213394

RESUMO

OBJECTIVE: To study the results of the second round in the subjects with negative tests in the first round of a prostate cancer screening program and to analyze the characteristics of the tumors that were not detected in the first round. METHODS: Of 5188 males evaluated in a prostate cancer screening program, 976 with negative tests in the first round (804 with PSA < or = 4 ng/ml; 172 with PSA > 4 ng/ml and a negative biopsy) accepted to undergo subsequent tests. During the second round, 163 biopsies were indicated. The biopsy results and the characteristics of the tumors detected were analyzed. RESULTS: The biopsy yield was higher (but not significantly) in the first round (80 cancers/481 biopsies; 16.6%) than in the second round (13 cancers/115 biopsies; 11.3%). Of the 163 biopsies indicated in the second round, 115 were performed and 13 cancers were detected (10 of these patients had a high PSA in the first round). The univariate analysis showed no differences for age, PSA, PSA density, prostate volume, transrectal US findings, or Gleason score in the cases diagnosed in the first round and those detected in the second round. However, there was a higher proportion of tumors with abnormal DRE in the cancers detected in the first round than in the second round, (31.3% vs 7.7%, respectively; p = 0.02). There was a higher proportion of tumors clinically detected in the second round than in the first round (100% vs 75%, respectively; p = 0.043). The multivariate analysis only showed differences for the DRE findings (p = 0.045). CONCLUSION: A significant number of tumors are undetected in prostate cancer screening programs. Although the biopsy yield may be slightly lower in subsequent rounds, there is a strong trend of detecting more localized tumors (and therefore potentially curable). We have found no correlation between a greater prostate volume and tumors that were undetected in the first round.


Assuntos
Neoplasias da Próstata/patologia , Idoso , Biópsia/estatística & dados numéricos , Reações Falso-Negativas , Humanos , Masculino , Programas de Rastreamento , Pessoa de Meia-Idade , Neoplasias da Próstata/epidemiologia , Controle de Qualidade
20.
Arch Esp Urol ; 52(7): 713-9, 1999 Sep.
Artigo em Espanhol | MEDLINE | ID: mdl-10540761

RESUMO

W. H. Wollaston, who first described cystine stones, as well as the most outstanding contemporary figures and their contribution to the understanding of this uncommon type of lithiasis are described.


Assuntos
Cistina/história , Cálculos Urinários/história , Europa (Continente) , História do Século XVIII , História do Século XIX , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...